The 'Ampyra' strikes slack: Phase III stroke bid kaput

Acorda Therapeutics Inc.'s phase III fizzle in post-stroke walking difficulties of potassium channel blocker Ampyra didn't put much of a dent in the stock, but it made for the second development halt this year and put pressure on the rest of the pipeline.